News
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health Announces First Quarter 2024 Results
Bausch Health Companies Inc. reports first quarter 2024 financial results with 11% revenue growth and continued year-over-year revenue increase in all segments. CEO Thomas J. Appio highlights focus on R&D pipeline, balance sheet strength, and global growth strategies -
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Bausch Health Companies Inc. and Salix Pharmaceuticals win U.S. Court of Appeals case over XIFAXAN, affirming FDA approval delay until Oct. 2029. Statements from CEOs included -
